Portal de Periódicos da CAPES

FOLFOX and FLOX Regimens for the Adjuvant Treatment of Resected Stage II and III Colon Cancer

2008; Taylor & Francis; Volume: 26; Issue: 9 Linguagem: Inglês

10.1080/07357900802132550

1532-4192

Saima Sharif, Michael J. O’Connell, Greg Yothers, Samia Lopa, Norman Wolmark,

Gastric Cancer Management and Outcomes

The MOSAIC trial showed that the use of adjuvant oxaliplatin and an infusional regimen of 5-FU/LV in the treatment of stage II/III colon cancer improved disease-free survival (DFS). The NSABP's C-07 trial evaluated the addition of oxaliplatin to a weekly Roswell Park regimen of bolus 5-FU/LV and found a similar improvement in DFS. The benefit of oxaliplatin appears to be independent of the 5-FU/LV regimen used. This paper reviews the efficacy and toxicities of these two regimens and is meant to serve as a guide for clinical practice.